Literature DB >> 28538263

BETTER PROGNOSIS FOR EYES WITH PRESERVED FOVEAL DEPRESSION AFTER INTRAVITREAL RANIBIZUMAB INJECTION FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.

Shuta Kitagawa1, Shunsuke Yasuda, Yasuki Ito, Shinji Ueno, Takeshi Iwase, Hiroko Terasaki.   

Abstract

PURPOSE: To determine the prognosis of eyes with central retinal vein occlusion that had a preserved foveal depression at the baseline and were treated by intravitreal ranibizumab injections (IRIs).
METHODS: The authors reviewed the medical records of 23 eyes of 23 consecutive treatment-naive patients who received IRIs to treat the macular edema due to central retinal vein occlusion. Eyes were classified by the pre-IRI presence or absence of a foveal depression. A foveal depression was defined as a central foveal thickness that was <50 μm thinner than the average thickness at 200 μm temporal and nasal to the central fovea. The characteristics of the two groups were compared.
RESULTS: Seven of 23 eyes had a preserved foveal depression before the IRI. The mean number of injections within 12 months after the initial IRI was significantly fewer (P < 0.001) in eyes with foveal depression (1.6 ± 0.5) than in eyes without foveal depression (4.3 ± 1.3). The mean best-corrected visual acuity at 12 months after the initial IRI was significantly better (P = 0.003) in eyes with foveal depression (0.10 ± 0.17 logarithm of the minimum angle of resolution [logMAR] units; 20/25 Snellen units) than in eyes without foveal depression (0.77 ± 0.54 logMAR units; 20/118 Snellen units).
CONCLUSION: These results indicate that the prognosis is better for eyes with a foveal depression before the IRI treatment for a macular edema secondary to central retinal vein occlusion.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28538263     DOI: 10.1097/IAE.0000000000001707

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  3 in total

Review 1.  [Biomarkers in the treatment of retinal vein occlusion].

Authors:  Jakob Siedlecki; Lars-Olof Hattenbach; Nikolas Feltgen; Siegfried G Priglinger
Journal:  Ophthalmologie       Date:  2022-10-06

2.  Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab.

Authors:  Kerr Brogan; Monica Precup; Amanda Rodger; David Young; David Francis Gilmour
Journal:  BMC Ophthalmol       Date:  2018-02-09       Impact factor: 2.209

3.  12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry.

Authors:  Mateusz Niedzwiecki; Adrian Hunt; Vuong Nguyen; Hemal Mehta; Catherine Creuzot-Garcher; Pierre-Henry Gabrielle; Martin Guillemin; Samantha Fraser-Bell; Jennifer Arnold; Ian L McAllister; Mark Gillies; Daniel Barthelmes
Journal:  Acta Ophthalmol       Date:  2021-09-13       Impact factor: 3.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.